Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
Diagnosis & Disease Information
Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Idasanutlin Does Not Improve OS in Relapsed/Refractory Acute Myeloid Leukemia
There was no survival improvement with idasanutlin in the overall population or among patients with wild-type TP53.
Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML
Ivosidenib plus azacitidine prolonged event-free and overall survival compared with azacitidine alone.
Idarubicin Hydrochloride Injection Recalled Due to Presence of Particulate in Vial
Idarubicin Hydrochloride Injection is indicated in combination with other approved anti-leukemic drugs for the treatment of acute myeloid leukemia in adults.
AML Incidence and Deaths Increasing Worldwide
Although mortality-to-incidence indices are improving globally, the increasing burden of AML is “concerning,” according to researchers.
Dioxin Exposure From Agent Orange Linked to AML and MDS
Researchers sought to examine relationships between leukemogenesis, Agent Orange, and a dioxin commonly found as a contaminant of Agent Orange.
Survival Inferior in Black Patients With Acute Myeloid Leukemia
Most disparities in acute myeloid leukemia death were accounted for by census tract measures.
Gilteritinib Provides Long-Term Benefit in Rel/Ref FLT3-Mutated Acute Myeloid Leukemia
The 2-year overall survival rate was 20.6% in the gilteritinib arm and 14.2% in the salvage chemotherapy arm.
Shifts Seen in Treatment Patterns for Older Patients With Acute Myeloid Leukemia
A new study shows a changing landscape of frontline treatment for older patients with acute myeloid leukemia and opportunities to increase treatment options.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...